Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies
The vital renal replacement therapy makes it impossible for dialysis patients to distance themselves socially. This results in a high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and developing coronavuris disease 2019, with excess mortality due to disease burden an...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
31 January 2022
|
| In: |
Nephrology, dialysis, transplantation
Year: 2022, Volume: 37, Issue: 6, Pages: 1132-1139 |
| ISSN: | 1460-2385 |
| DOI: | 10.1093/ndt/gfac018 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/ndt/gfac018 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/ndt/article/37/6/1132/6517745?login=true 
|
| Author Notes: | Niko Kohmer, Holger F. Rabenau, Sandra Ciesek, Bernhard K. Krämer, Uwe Göttmann, Christine Keller, Daniela Rose, Carsten Blume, Michael Thomas, Alexander Lammert and Anne Lammert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1881575683 | ||
| 003 | DE-627 | ||
| 005 | 20240325174228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ndt/gfac018 |2 doi | |
| 035 | |a (DE-627)1881575683 | ||
| 035 | |a (DE-599)KXP1881575683 | ||
| 035 | |a (OCoLC)1425215266 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kohmer, Niko |d 1988- |e VerfasserIn |0 (DE-588)1120509572 |0 (DE-627)873452909 |0 (DE-576)480390444 |4 aut | |
| 245 | 1 | 0 | |a Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients |b seroconversion and presence of neutralizing antibodies |c Niko Kohmer, Holger F. Rabenau, Sandra Ciesek, Bernhard K. Krämer, Uwe Göttmann, Christine Keller, Daniela Rose, Carsten Blume, Michael Thomas, Alexander Lammert and Anne Lammert |
| 264 | 1 | |c 31 January 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.02.2024 | ||
| 520 | |a The vital renal replacement therapy makes it impossible for dialysis patients to distance themselves socially. This results in a high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and developing coronavuris disease 2019, with excess mortality due to disease burden and immunosuppression. We determined the efficacy of a 100-µg booster of mRNA-1273 (Moderna, Cambridge, MA, USA) 6 months after two doses of BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, USA) in 194 SARS-CoV-2-naïve dialysis patients.Anti-SARS-CoV-2 spike antibodies were measured with the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, Mannheim, Germany) 4 and 10-12 weeks after two doses of BNT162b2 as well as 4 weeks after the mRNA-1273 booster. The presence of neutralizing antibodies was measured by the SARS-CoV-2 Surrogate Virus Neutralization Test (GenScript Biotech, Piscataway, NJ, USA). Two different cut-offs for positivity were used, one according to the manufacturer's specifications and one correlating with positivity in a plaque reduction neutralization test (PRNT). Receiver operating characteristics analyses were performed to match the anti-SARS-CoV-2 spike antibody cut-offs with the cut-offs in the surrogate neutralization assay accordingly.Any level of immunoreactivity determined by the anti-SARS-CoV-2 spike antibody assay was found in 87.3% (n = 144/165) and 90.6% (n = 164/181) of patients 4 and 10-12 weeks, respectively, after two doses of BNT162b2. This was reduced to 68.5% or 60.6% 4 weeks and 51.7% or 35.4% 10-12 weeks, respectively, when using the ROC cut-offs for neutralizing antibodies in the surrogate neutralization test (manufacturer's cut-off ≥103 U/mL and cut-off correlating with PRNT ≥196 U/mL). Four weeks after the mRNA-1273 booster, the concentration of anti-SARS-CoV-2 spike antibodies increased to 23 119.9 U/mL and to 97.3% for both cut-offs of neutralizing antibodies.Two doses of BNT162b2 followed by one dose of mRNA-1273 within 6 months in patients receiving maintenance dialysis resulted in significant titres of SARS-CoV-2 spike antibodies. While two doses of mRNA vaccine achieved adequate humoral immunity in a minority, the third vaccination boosts the development of virus-neutralizing quantities of SARS-CoV-2 spike antibodies (against wild-type SARS-CoV-2) in almost all patients. | ||
| 700 | 1 | |a Rabenau, Holger F |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ciesek, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krämer, Bernhard |d 1957- |e VerfasserIn |0 (DE-588)14017589X |0 (DE-627)70358927X |0 (DE-576)314926852 |4 aut | |
| 700 | 1 | |a Göttmann, Uwe |d 1974- |e VerfasserIn |0 (DE-588)124642071 |0 (DE-627)575608722 |0 (DE-576)294426175 |4 aut | |
| 700 | 1 | |a Keller, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rose, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blume, Carsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lammert, Alexander |d 1975- |e VerfasserIn |0 (DE-588)129092738 |0 (DE-627)389525898 |0 (DE-576)188420983 |4 aut | |
| 700 | 1 | |a Lammert, Anne |d 1983- |e VerfasserIn |0 (DE-588)137533365 |0 (DE-627)695845284 |0 (DE-576)303406097 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation |d Oxford : Oxford Univ. Press, 1986 |g 37(2022), 6 vom: Juni, Seite 1132-1139 |h Online-Ressource |w (DE-627)265778395 |w (DE-600)1465709-0 |w (DE-576)079420079 |x 1460-2385 |7 nnas |a Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients seroconversion and presence of neutralizing antibodies |
| 773 | 1 | 8 | |g volume:37 |g year:2022 |g number:6 |g month:06 |g pages:1132-1139 |g extent:8 |a Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients seroconversion and presence of neutralizing antibodies |
| 856 | 4 | 0 | |u https://doi.org/10.1093/ndt/gfac018 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/ndt/article/37/6/1132/6517745?login=true |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240226 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 137533365 |a Lammert, Anne |m 137533365:Lammert, Anne |d 60000 |d 62100 |e 60000PL137533365 |e 62100PL137533365 |k 0/60000/ |k 1/60000/62100/ |p 11 |y j | ||
| 998 | |g 129092738 |a Lammert, Alexander |m 129092738:Lammert, Alexander |d 60000 |e 60000PL129092738 |k 0/60000/ |p 10 | ||
| 998 | |g 124642071 |a Göttmann, Uwe |m 124642071:Göttmann, Uwe |d 60000 |e 60000PG124642071 |k 0/60000/ |p 5 | ||
| 998 | |g 14017589X |a Krämer, Bernhard |m 14017589X:Krämer, Bernhard |d 60000 |d 61400 |e 60000PK14017589X |e 61400PK14017589X |k 0/60000/ |k 1/60000/61400/ |p 4 | ||
| 999 | |a KXP-PPN1881575683 |e 4491096252 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 26.02.2024"],"origin":[{"dateIssuedDisp":"31 January 2022","dateIssuedKey":"2022"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":"seroconversion and presence of neutralizing antibodies","title_sort":"Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients","title":"Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients"}],"language":["eng"],"person":[{"family":"Kohmer","display":"Kohmer, Niko","given":"Niko","role":"aut"},{"display":"Rabenau, Holger F","family":"Rabenau","given":"Holger F","role":"aut"},{"given":"Sandra","role":"aut","family":"Ciesek","display":"Ciesek, Sandra"},{"role":"aut","given":"Bernhard","display":"Krämer, Bernhard","family":"Krämer"},{"given":"Uwe","role":"aut","family":"Göttmann","display":"Göttmann, Uwe"},{"given":"Christine","role":"aut","display":"Keller, Christine","family":"Keller"},{"given":"Daniela","role":"aut","display":"Rose, Daniela","family":"Rose"},{"display":"Blume, Carsten","family":"Blume","given":"Carsten","role":"aut"},{"family":"Thomas","display":"Thomas, Michael","given":"Michael","role":"aut"},{"family":"Lammert","display":"Lammert, Alexander","role":"aut","given":"Alexander"},{"role":"aut","given":"Anne","family":"Lammert","display":"Lammert, Anne"}],"id":{"eki":["1881575683"],"doi":["10.1093/ndt/gfac018"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1986 -"],"recId":"265778395","id":{"eki":["265778395"],"issn":["1460-2385"],"zdb":["1465709-0"]},"disp":"Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients seroconversion and presence of neutralizing antibodiesNephrology, dialysis, transplantation","origin":[{"publisher":"Oxford Univ. Press","dateIssuedKey":"1986","publisherPlace":"Oxford","dateIssuedDisp":"1986-"}],"note":["Gesehen am 01-04-14"],"titleAlt":[{"title":"Nephrology, dialysis, transplantation online"}],"title":[{"title":"Nephrology, dialysis, transplantation","title_sort":"Nephrology, dialysis, transplantation"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"37(2022), 6 vom: Juni, Seite 1132-1139","pages":"1132-1139","year":"2022","volume":"37","extent":"8","issue":"6"},"language":["eng"]}],"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Niko Kohmer, Holger F. Rabenau, Sandra Ciesek, Bernhard K. Krämer, Uwe Göttmann, Christine Keller, Daniela Rose, Carsten Blume, Michael Thomas, Alexander Lammert and Anne Lammert"]},"recId":"1881575683"} | ||
| SRT | |a KOHMERNIKOHETEROLOGO3120 | ||